Imperial College London
Portrait Picture

ProfessorNagyHabib

Faculty of Medicine, Department of Surgery & Cancer

Professor of Hepatobiliary Surgery
 
 
 
//

Contact

 

+44 (0)20 3313 8574nagy.habib

 
 
//

Assistant

 

Mrs Benita White +44 (0)7960 986 387

 
//

Location

 

BN1/18 B BlockHammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Kwok:2019:10.4155/tde-2018-0061,
author = {Kwok, A and Raulf, N and Habib, N},
doi = {10.4155/tde-2018-0061},
journal = {Ther Deliv},
pages = {151--164},
title = {Developing small activating RNA as a therapeutic: current challenges and promises.},
url = {http://dx.doi.org/10.4155/tde-2018-0061},
volume = {10},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - RNA activation (RNAa) allows specific gene upregulation mediated by a small activating RNA (saRNA). Harnessing this process would help in developing novel therapeutics for undruggable diseases. Since its discovery in mid 2000s, improvements of saRNA design, synthetic chemistry and understanding of the biology have matured the way to apply RNAa. Indeed, MiNA therapeutics Ltd has conducted the first RNAa clinical trial for advanced hepatocellular carcinoma patients with promising outcomes. However, to fully realize the RNAa potential better saRNA delivery strategies are needed to target other diseases. Currently, saRNA can be delivered in vivo by lipid nanoparticles, dendrimers, lipid and polymer hybrids and aptamers. Further developing these delivery technologies and novel application of RNAa will prove to be invaluable for new treatment development.
AU  - Kwok,A
AU  - Raulf,N
AU  - Habib,N
DO  - 10.4155/tde-2018-0061
EP  - 164
PY  - 2019///
SP  - 151
TI  - Developing small activating RNA as a therapeutic: current challenges and promises.
T2  - Ther Deliv
UR  - http://dx.doi.org/10.4155/tde-2018-0061
UR  - https://www.ncbi.nlm.nih.gov/pubmed/30909853
VL  - 10
ER  -
Download